Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, October 23, 2013

Opexa Therapeutics Immune Monitoring Program Featured in Neurology Reviews FOR SPMS

THE WOODLANDS, Texas, Oct 21, 2013 (BUSINESS WIRE) -- Opexa Therapeutics, Inc., a biotechnology company developing Tcelna(R), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the Company has been featured in Neurology Reviews. The article, titled "Regulation May Be Impaired in Patients With Secondary Progressive MS," was written by Erik Greb, the publication's senior associate editor, and presents data from Opexa's Immune Monitoring program that is part of its ongoing Phase IIb Abili-T trial in Secondary Progressive MS (SPMS).
The article presents baseline data on Opexa's Immune Monitoring Program that was previously presented at the 2013 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting. The immune monitoring data will be used to assess the impact of Tcelna in SPMS patients compared to patients receiving placebo. Opexa's data supports the finding that immune regulation appears to be impaired in individuals with SPMS. Opexa characterized the status of patients with SPMS entering the Phase IIb trial at baseline and compared the data sets to those of healthy donors. The results showed a marked difference between key biomarkers of inflammation, specifically TR1 and Treg cells, in patients suffering from SPMS versus healthy donors. The results corroborated findings in the literature and provide support for the assays being utilized by Opexa for the immune monitoring program.
"As part of our Phase IIb Abili-T trial, we are undertaking a comprehensive immune monitoring program for all patients enrolled in the study," commented Donald Healey, PhD, Chief Scientific Officer at Opexa. "The goals of this program are to further understand the biology behind the mechanism of action for Tcelna and to possibly identify novel biomarkers that are dominant in the pathophysiology of SPMS patients. 
READ MORE FROM HERE
……..

To comment - click the comment link shown below
…….
USE OUR SHARE LINKS at the top of this page  - to provide this article to others
……
REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
…………………….
.

No comments: